Pulmonary administration of chemically modified insulin
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
25 Citations
77 Claims
-
1-38. -38. (canceled)
-
39. A method for providing a substantially non-immunogenic insulin composition for administration to the lung of a subject in need thereof, said method comprising:
-
covalently coupling insulin to one or more molecules of a non-naturally occurring hydrophilic polymer to provide a composition comprising an insulin-hydrophilic polymer conjugate, and administering said composition to the lung of a subject in need thereof by inhalation, whereby as a result of said administering, said insulin passes through the lung and enters into the blood circulation. - View Dependent Claims (40)
-
-
41. A method for providing a prolonged-effect insulin composition for administration to the lung of a subject in need thereof, said method comprising:
-
covalently coupling insulin to one or more molecules of a non-naturally occurring hydrophilic polymer to provide a composition comprising an insulin-hydrophilic polymer conjugate, administering said composition to the lung of a subject in need thereof by inhalation, whereby as a result of said administering, (i) said insulin passes through the lung and enters the blood circulation, and (ii) elevated blood levels of insulin are sustained for at least 8 hours post administration. - View Dependent Claims (42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)
-
Specification